Patny Akshay, Desai Prashant V, Avery Mitchell A
Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, Mississippi 38677-1848, USA.
Proteins. 2006 Dec 1;65(4):824-42. doi: 10.1002/prot.21196.
Angiotensin II type 1 (AT(1)) receptor belongs to the super-family of G-protein-coupled receptors, and antagonists of the AT(1) receptor are effectively used in the treatment of hypertension. To understand the molecular interactions of these antagonists, such as losartan and telmisartan, with the AT(1) receptor, a homology model of the human AT(1) (hAT(1)) receptor with all connecting loops was constructed from the 2.6 A resolution crystal structure (PDB i.d., 1L9H) of bovine rhodopsin. The initial model generated by MODELLER was subjected to a stepwise ligand-supported model refinement. This protocol involved initial docking of non-peptide AT(1) antagonists in the putative binding site, followed by several rounds of iterative energy minimizations and molecular dynamics simulations. The final model was validated based on its correlation with several structure-activity relationships and site-directed mutagenesis data. The final model was also found to be in agreement with a previously reported AT(1) antagonist pharmacophore model. Docking studies were performed for a series of non-peptide AT(1) receptor antagonists in the active site of the final hAT(1) receptor model. The docking was able to identify key molecular interactions for all the AT(1) antagonists studied. Reasonable correlation was observed between the interaction energy values and the corresponding binding affinities of these ligands, providing further validation for the model. In addition, an extensive unrestrained molecular dynamics simulation showed that the docking-derived bound pose of telmisartan is energetically stable. Knowledge gained from the present studies can be used in structure-based drug design for developing novel ligands for the AT(1) receptor.
血管紧张素II 1型(AT(1))受体属于G蛋白偶联受体超家族,AT(1)受体拮抗剂可有效用于治疗高血压。为了解这些拮抗剂(如氯沙坦和替米沙坦)与AT(1)受体的分子相互作用,利用牛视紫红质2.6 Å分辨率的晶体结构(蛋白质数据库编号,1L9H)构建了具有所有连接环的人AT(1)(hAT(1))受体同源模型。由MODELLER生成的初始模型经过逐步的配体支持模型优化。该方案包括将非肽类AT(1)拮抗剂初步对接至假定的结合位点,随后进行几轮迭代能量最小化和分子动力学模拟。基于最终模型与几种构效关系和定点诱变数据的相关性对其进行验证。还发现最终模型与先前报道的AT(1)拮抗剂药效团模型一致。在最终的hAT(1)受体模型的活性位点对一系列非肽类AT(1)受体拮抗剂进行对接研究。对接能够确定所研究的所有AT(1)拮抗剂的关键分子相互作用。观察到这些配体的相互作用能值与相应结合亲和力之间存在合理的相关性,为该模型提供了进一步的验证。此外,广泛的无约束分子动力学模拟表明,替米沙坦对接衍生的结合构象在能量上是稳定的。从本研究中获得的知识可用于基于结构的药物设计,以开发新型的AT(1)受体配体。